Edgar Filing: Ohr Pharmaceutical Inc

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐

Definitive Proxy Statement

☒

Definitive Additional Materials

☐

Soliciting Material Pursuant to §240.14a-12

Ohr Pharmaceutical, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒

No fee required.

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

☐

Fee paid previously with preliminary materials.

☐

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount Previously Paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:

Ohr Pharmaceutical, Inc.

P.O. BOX 8016
CARY, NC 27512-9903

Important Notice Regarding the Availability of Proxy Materials for Ohr Pharmaceutical, Inc.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to www.proxydocs.com/OHRP. To vote your proxy while visiting this site you will need the 12-digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to adopt these rules and need YOUR participation.

If you want to receive a paper or e-mail notice of the proxy material, you may request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s annual meeting, you must make this request on or before April 4, 2017.

		CONTROL NUMBER

	CLIENT:
	EVENT:
	ACCT #:

For a convenient way to view proxy materials and VOTE
go to: www.proxydocs.com/OHRP

Have the 12-digit control number located in the shaded box above
available when you access the website and follow the instructions.

To order paper materials, use one of the following methods:


INTERNET	TELEPHONE	* E-MAIL
www.investorelections.com/OHRP	(866) 648-8133	paper@investorelections.com

When requesting via the internet or telephone, you will need the 12-digit control number located in the shaded box above.		* If requesting material by e-mail, please send a blank e-mail with the 12-digit control number (located above) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.


Ohr Pharmaceutical, Inc. Notice of the 2017 Annual Meeting

The 2017 Annual Meeting of Stockholders of Ohr Pharmaceutical, Inc., will be held on Friday, April 14, 2017, at 11:00 am, Local Time, at the offices of Troutman Sanders LLP, 875 Third Avenue, New York, NY 10022 for the following purposes:

The Board of Directors recommends a vote FOR all the named nominees as directors, and FOR Proposals 2 and 3.

1. To elect two directors to hold office until the 2020 Annual Meeting of Stockholders;
	01. June S. Almenoff, M.D. PH.D.
	02. Thomas Reidhammer, PH.D.

2. To approve a non-binding advisory resolution on executive compensation.

3. To ratify the selection of MaloneBailey, LLP as our independent auditors for the 2017 fiscal year; and

4. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.